{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:09:41Z","timestamp":1784740181836,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s13555-024-01150-y","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T20:29:32Z","timestamp":1713817772000},"page":"1327-1335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month\u00a012 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2765-5417","authenticated-orcid":false,"given":"Elisabeth","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Zaheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brnabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Konicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed El","family":"Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Haustrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40257-021-00622-7","volume":"22","author":"C Blome","year":"2021","unstructured":"Blome C, Augustin M, Klein TM. Nail psoriasis and quality-of-life measurement in clinical trials: call for the use of nail-specific instruments. Am J Clin Dermatol. 2021;22:747\u201355.","journal-title":"Am J Clin Dermatol"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40744-023-00553-1","volume":"10","author":"BW Kirkham","year":"2023","unstructured":"Kirkham BW, Egeberg A, Behrens F, et al. A comprehensive review of ixekizumab efficacy in nail psoriasis from clinical trials for moderate-to-severe psoriasis and psoriatic arthritis. Rheumatol Ther. 2023;10:1127\u201346.","journal-title":"Rheumatol Ther"},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","volume":"78","author":"BE Elewski","year":"2018","unstructured":"Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26\u00a0weeks of a phase\u00a03, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78:90\u20139.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"2263108","DOI":"10.1080\/09546634.2023.2263108","volume":"34","author":"A Egeberg","year":"2023","unstructured":"Egeberg A, Kristensen LE, Puig L, et al. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24\u201328 and 48\u201352\u00a0weeks. J Dermatol Treat. 2023;34:2263108.","journal-title":"J Dermatol Treat"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaad.2021.01.024","volume":"85","author":"IH Huang","year":"2021","unstructured":"Huang IH, Wu PC, Yang TH, et al. Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;85:135\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"1150_CR6","doi-asserted-by":"crossref","unstructured":"Bardazzi F, Antonucci VA, Tengattini V, et al. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis. J Dtsch Dermatol Ges. 2013;11:1065\u201370.","DOI":"10.1111\/ddg.12173"},{"key":"1150_CR7","doi-asserted-by":"publisher","unstructured":"Pinter A, Costanzo A, Khattri S, et al. Comparative effectiveness and durability of biologics in clinical practice: month 12 outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatol Ther (Heidelb). 2023. https:\/\/doi.org\/10.1007\/s13555-023-01086-9.","DOI":"10.1007\/s13555-023-01086-9"},{"key":"1150_CR8","doi-asserted-by":"crossref","unstructured":"Pinter A, Puig L, Sch\u00e4kel K, et al. Comparative effectiveness of biologics in clinical practice: week\u00a012 primary outcomes from an International Observational Psoriasis Study of Health Outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087\u20132100.","DOI":"10.1111\/jdv.18376"},{"key":"1150_CR9","doi-asserted-by":"crossref","unstructured":"Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week\u00a012 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med (Lausanne). 2023;10:1185523.","DOI":"10.3389\/fmed.2023.1185523"},{"key":"1150_CR10","first-page":"123","volume":"34","author":"SE Cassell","year":"2007","unstructured":"Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34:123\u20139.","journal-title":"J Rheumatol"},{"key":"1150_CR11","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184:1047\u201358.","DOI":"10.1111\/bjd.19509"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01150-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01150-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01150-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T13:27:18Z","timestamp":1716470838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01150-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01150-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elisabeth Riedl is a former employee, has pending patents with Eli Lilly and Company and has also been a speaker and\/or consultant for Eli Lilly and Company, Pelpharma, Novartis, Almirall. Andreas Pinter has served as an investigator, speaker,\u00a0and\/or\u00a0consultant\u00a0for\u00a0AbbVie, Almirall-Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, GSK, Eli Lilly and Company, Galderma, Hexal, Janssen, LEO Pharma, MC2,\u00a0Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough und UCB Pharma. Shirin Zaheri\u00a0has served as advisory board member or has received fees and speaker\u2019s honoraria for AbbVie, Biogen, Eli Lilly and Company, Leo Pharma, L\u2019Or\u00e9al and Novartis. Antonio Costanzo served as advisory board member and consultant, and\/or has received fees and\/or speaker\u2019s honoraria and\/or has participated to clinical trials for Abbvie, Almirall, Amgen, Eli Lilly and Company, Janssen, Novartis, Sanofi and UCB and is president of European Dermatology Forum and has received payment to participate on the advisory boards for IQVIA. Alan Brnabic, Bruce Konicek, Robert McKenzie, Anastasia Lampropoulou, Mohamed El Rayes, Natalie Haustrup, Christopher Schuster are all employees and minor shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol, amendments, and consent documentation were approved by local institutional review boards (IRB). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and\/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}